caris life sciences® - mi folfoxai™ - mcrc treatment predictor
Published 3 years ago • 309 plays • Length 9:16Download video MP4
Download video MP3
Similar videos
-
4:49
caris life sciences - powering precision medicine for cancer patients
-
1:01
a better way to fight cancer | caris molecular profiling
-
3:05
tissue-based comprehensive molecular profiling
-
50:58
fom lecture 1: dr. david spetzler, caris life sciences
-
3:01
deeper: m-folfoxiri and cetuximab versus bevacizumab in mcrc
-
2:40
folfoxiri plus panitumumab vs mfolfox6/pan for unresectable ras and braf wild-type mcc
-
2:31
difference between primary and metastatic cancer | central principles of molecular biology
-
1:29
dr. cremolini on folfoxiri plus bevacizumab for metastatic colorectal cancer
-
53:55
episode 12: dr. steven gundry on harnessing polyphenols for optimal health
-
13:32
what is folfox chemotherapy?
-
4:19
what is ngs and how does it work? | central principles of molecular biology
-
2:21
caris life sciences to present new ovarian cancer research at esmo 2020 - w. michael korn, md, cmo
-
3:58
dr. cathy eng on bevacizumab plus folfoxiri for patients with mcrc
-
2:45
1l folfoxiri plus cetuximab or bevacizumab for ras wild-type mcrc
-
0:53
caris life sciences blood lab drone tour
-
0:30
what do the stages of colorectal cancer mean? - dr. kabir mody
-
4:16
second-line therapy for ras wild-type mcrc
-
1:18
second line and later therapies - metastatic colorectal cancer
-
39:50
evolution in oncology - caris life sciences and concertai
-
3:18
conversion from unresectable to resectable mcrc in real-world patients
-
8:42
frontline therapy for mcrc
-
12:20
metastatic colorectal cancer: expert perspectives on improving care